Low 2-Dimensional CD4 T Cell Receptor Affinity for Myelin Sets in Motion Delayed Response Kinetics by Rosenthal, Kristen M. et al.
Low 2-Dimensional CD4 T Cell Receptor Affinity for
Myelin Sets in Motion Delayed Response Kinetics
Kristen M. Rosenthal
1, Lindsay J. Edwards
1, Joseph J. Sabatino Jr




2, Brian D. Evavold
1*
1Department of Microbiology and Immunology, Emory University, Atlanta, Georgia, United States of America, 2Coulter Department of Biomedical Engineering, Georgia
Institute of Technology, Atlanta, Georgia, United States of America
Abstract
T cells recognizing self-peptides that mediate autoimmune disease and those that are responsible for efficacious immunity
against pathogens may differ in affinity for antigen due to central and peripheral tolerance mechanisms. Here we utilize
prototypical self-reactive (myelin) and viral-specific (LCMV) T cells from T cell receptor (TCR) transgenic mice (2D2 and
SMARTA, respectively) to explore affinity differences. The T cells responsive to virus possessed .10,000 fold higher 2D
affinity as compared to the self-reactive T cells. Despite their dramatically lower affinity for their cognate ligand, 2D2 T cells
respond with complete, albeit delayed, activation (proliferation and cytokine production). SMARTA activation occurs rapidly,
achieving peak phosphorylation of p38 (1 minute), Erk (30 minutes), and Jun (3 hours) as well as CD69 and CD25
upregulation (3 and 6 hours, respectively), with a corresponding early initiation of proliferation. 2D2 stimulation with MOG
results in altered signaling – no phospho-Erk or phospho-p38 accumulation, significantly delayed activation kinetics of Jun
(12 hours), and delayed but sustained SHP-1 activity – as well as delayed CD69 and CD25 expression (12–24 hours), and
slow initiation of proliferation. This delay was not intrinsic to the 2D2 T cells, as a more potent antigen with .100-fold
increased 2D affinity restored rapid response kinetics in line with those identified for the viral antigen. Taken together, these
data demonstrate that time can offset low TCR affinity to attain full activation and suggest a mechanism by which low
affinity T cells participate in autoimmune disease.
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Introduction
Every T cell must be able to differentiate between high and low
potency ligands to generate the appropriate response after T cell
receptor (TCR) binding [1–3], as antigens vary in their capacity to
stimulate a given T cell. The library of peptides for a specific TCR
includes agonists, partial or weak agonists, and antagonists [4]. In
the case of CD8+ OT-I T cells, these ligands can span a .1,000
fold range in effective 2D affinity [5]. The TCR can thus integrate
the strength of ligand binding and impart the appropriate
response, ranging from full activation to anergy to antagonism
[6,7].
Generally, self-reactive T cells mediating autoimmune disease
are thought to be lower affinity than pathogen-specific T cells due
to various tolerance mechanisms [8,9]. Recently, we utilized a
micropipette-based assay (where both the TCR and pMHC are
membrane-bound) to assess the effective 2D affinity of T cells
during various immune responses [10]. This report identified
participation of lower affinity T cells in both pathogenic and
autoimmune responses, although stimulation with a myelin-
specific self-peptide important in murine EAE induction
(MOG35–55) results in a greater frequency of tetramer negative
low affinity T cells as compared to a pathogen-derived epitope in
murine LCMV (gp61–80) [10].
When shaping an immune response, both the TCR affinity and
duration of antigen encounter play roles in directing the outcome
of T cell activation. During an acute infection, the presence of
foreign antigen is transient and allows for robust T cell expansion
followed by contraction to the memory state as pathogen is cleared
[11]. During chronic infections, pathogenic antigens can be
present for an extended time, which can lead to deletion or
exhaustion of the T cells [12–14]. Self-peptide antigens are
constantly produced and presented [15,16], yet intriguingly, T
cells that propagate autoimmune disease can seemingly avoid
exhaustion or regulation.
As a first step to understand the apparent differences in T cell
activation, we utilized LCMV specific (SMARTA) [17,18] and
myelin-reactive (2D2) [19] CD4
+ TCR transgenic mouse models
and identified a .10,000 fold lower effective 2D affinity in 2D2 T
cells that resulted in a substantial decrease in functional sensitivity
to myelin and a complete absence of peptide:MHC class II
tetramer reactivity. In spite of this dramatically decreased affinity
for cognate ligand, 2D2 T cells successfully proliferated and
produced cytokines, although with a temporal delay in the T cell
response that manifested as an absence of detectable phosphor-
ylated Erk and p38 and significantly delayed activation kinetics of
SHP-1, Jun, CD69, and CD25. In contrast, activation occurred
rapidly in the pathogen specific T cells. The delay in response to
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e32562myelin was not intrinsic to the self-reactive T cells, as the 2D2
response to a more potent antigen with a .100-fold increase in
effective 2D affinity gave rapid response kinetics. Moreover, the
low-affinity MOG peptide must be displayed for a protracted time
to initiate a robust response. Our data demonstrate that extended
time of antigen presentation can compensate for lower TCR
affinity for self and allow for accumulation of signals and eventual
full activation of CD4
+ T cells.
Results
The relative 2D affinity of CD4
+ T cells
Using a micropipette-based binding assay the effective two-
dimensional (2D) affinity, which measures receptor:ligand binding
in the context of a cell membrane, can define differences in affinity
of TCR:pMHC with greater resolution than other measurements
[5,10]. In this assay, a single T cell is brought in and out of contact
with a red blood cell (RBC) coated with pMHC class II monomers
to yield an adhesion probability (the percentage of adhesions out of
the total number of contacts). The adhesion probability allows for
derivation of the effective 2D affinity of the TCR:pMHC
[5,20,21]. SMARTA TCR interacts with gp66–77:I-A
b with high
affinity (Figure 1a). In contrast, adhesion of 2D2 CD4
+ T cells to
RBCs coated with .2000 molecules/um
2 MOG38–49:I-A
b was still
negligible, indicating a ,10
28 mm
4 affinity (Figure 1a). It has
recently been shown that, in addition to MOG, 2D2 T cells can
respond better to a CNS self-epitope from the neurofilament
medium chain (NFM) [22]. NFM15–35 contains 6 out of 9 identical
amino acid residues to the core epitope of MOG35–55 and
conserves all of the recognized TCR contact residues [22]. In
contrast to MOG35–55, the adhesion between 2D2 TCR and
NFM18–30:I-A
b is measurable in the micropipette assay and results
in an affinity approximately 80-fold lower than that of SMARTA
T cells (9.22610
26 mm
4 compared to 7.32610
24 mm
4) (Figure 1a).
Another gauge of TCR affinity uses the extent of peptide:MHC
II tetramer staining detected by flow cytometry [23–25].
Previously, pMHC II tetramers were shown to detect MOG35–55
CD4
+ T cells in EAE [10,26,27], but on detailed analysis, MOG:I-
A
b tetramer failed to identify most of the MOG-specific T cells
[10]. In accordance with the undetectable 2D affinity of MOG:I-
A
b interaction with 2D2 TCR, there was a lack of MOG:I-A
b
tetramer staining in 2D2 T cells, whereas all of the SMARTA T
cells were positive for tetramer staining (Figure 1b).
Peptides, particularly longer peptides, may bind to MHC class
II molecules in multiple 9-mer epitopes, or registers [28–32]. To
define the 2D2 T cells’ response to the core epitope engineered
into the MOG38–49:I-A
b monomer, we assessed the proliferative
capacity of 2D2 T cells to a panel of overlapping, truncated
peptides from the MOG35–55 sequence (Table I). This assay
revealed that the core epitope for 2D2 T cells is MOG39–48, which
is the basis of the MOG:I-A
b construct (Table I), and
demonstrated that the absence of MOG:I-A
b reactivity in
tetramers or by 2D micropipette analysis was not due to the
register of the antigenic epitope.
Functional avidity of CD4
+ T cells
T cell functional avidity, defined by the amount of antigen
needed for half-maximal response, is often used as a surrogate of
TCR affinity for expressing the potency of an antigen [33–36].
SMARTA splenocytes showed some proliferation at the lowest
dose of gp61 tested (30 pM) while 2D2 splenocytes did not
respond until much higher doses of MOG were reached (0.3–
1 mM) (Figure 2a). Indeed, the EC50 of 2D2 T cells for MOG was
more than 3,000 times higher than that of SMARTA T cells
(3.3 mM compared to 0.001 mM) (Figure 2b). Although MOG:2D2
binding is too weak to be detected by either flow cytometry or 2D
micropipette analysis, stimulation with this self-peptide still
resulted in activation of 2D2 T cells. 2D2 cells responded to
lower doses of NFM (starting at 1 nM) and by EC50 required
approximately 10-fold more peptide than that of SMARTA cells
(,0.01 vs 0.001 mM) and 100-fold less peptide than that of 2D2
cells stimulated with MOG (,3 mM) (Figure 2a,c). Additionally,
antigen-dependent cytokine production, assessed by IL-2 produc-
tion, paralleled the proliferative capacity of the cells (Figure 2d). A
similar trend was observed with IFN-c –in that 2D2:MOG
stimulation resulted in less cytokine production than either
Figure 1. The effective 2D affinity of 2D2 and SMARTA CD4
+ T cells differs. (A) 2D2 or SMARTA T cells were stained with antigen-specific I-
A
b tetramer (MOG38–49 or gp66–77, respectively) or a negative control I-A
b tetramer and analyzed by flow cytometry, gated on CD4
+ cells. (B) Human
RBCs were coated with the indicated pMHC complex and brought into contact with the corresponding T cell by micropipette numerous times. The
resulting adhesion frequency was used to derive the effective 2D affinity (AcKa,i nmm
4). All experiments were performed at least three times.
doi:10.1371/journal.pone.0032562.g001
Low CD4 TCR Affinity Results in Delayed Response
PLoS ONE | www.plosone.org 2 March 2012 | Volume 7 | Issue 3 | e32562SMARTA:gp61 or 2D2:NFM across the range of antigen
concentrations (Figure 2e). Some have previously reported that
low affinity T cell stimulation can result in cytokine skewing to a
Th2 response [37]; however further cytokine analysis revealed
2D2:MOG produced lower amounts of IL-2 and IFN-c than
either SMARTA:gp61 or 2D2:NFM (P=0.0018 and P=0.005,
respectively) with only minimal levels of IL-4 produced regardless
of the antigen (Figure 2f). Taken together, this suggests that
although 2D2:MOG results in less cytokine production, there is no
evidence of phenotypic skewing.
Thus, 2D2 T cells have a relatively high functional avidity for
NFM, with proliferation and IL-2 production closer to the
corresponding functional avidity of SMARTA cells than to 2D2
cells for MOG (Figure 2). The hierarchy of the ligands shows that
SMARTA:gp61, a TCR:foreign antigen interaction, is the most
potent, followed by 2D2:NFM and, finally, 2D2:MOG. Overall, the
effective 2D affinities of these CD4
+ T cell clones for their ligand
correlates to some extent with their functional avidity (Figure 2c).
Altered signaling events in low affinity CD4
+ T cells
Erk plays a key role in positive T cell signaling events [38,39],
although it has been noted that in human cells Erk signaling can
contribute to limitation of naı ¨ve T cell activation [40]. To explore
the impact that TCR affinity has on T cell activation, phos-
phorylation of Erk in the MAP kinase pathway was analyzed.
Phosphorylation events were visualized by flow cytometry to allow
for detection and isolation of CD4
+ T cells from other cell types
[41]. Upon activation with gp61, SMARTA CD4
+ T cells showed
rapid phosphorylation of Erk1/2 by 5 min, peaking at 30 min,
and remaining phosphorylated through 6 h (Figure 3a and c).
Conversely, stimulation of 2D2 CD4
+ T cells with MOG showed
no appreciable accumulation of pErk at any time, from 5 min
through 24 hours (Figure 3a and c). Activation of 2D2 CD4
+ T
cells with the higher 2D affinity NFM ligand resulted in up-
regulation of pErk by 5 to 15 min, peaking at 60 min before slowly
declining by 24 h (Figure 3a and c). The NFM response confirms
that the 2D2 cells are not intrinsically deficient in their signaling
capacity. This data highlights that, despite proliferative and
cytokine responses (Figure 2), there is a dramatic difference in the
initial signaling program of high (SMARTA and NFM) versus low
(MOG) affinity agonists.
Although there is no notable accumulation of phosphorylated
Erk upon 2D2 TCR ligation with MOG, T cell stimulation with
low affinity ligands can allow highly reversible events, such as
phosphorylation of Erk, to revert quickly back to the basal state,
thus precluding detection by biochemical methods [42]. To
determine if Erk phosphorylation plays a role in 2D2 T cell
activation with MOG antigen, we assessed proliferation in the
presence of the MEK1/2 inhibitor, U0126. At 10 mM, this
inhibitor specifically targets MEK1/2 to inhibit the activation of
Erk1/2 without acting on p38 MAPK, JNK, protein kinase C, or
other pathways [43]. Treating 2D2 T cells with 10 mM U0126
prior to MOG stimulation resulted in a marked decrease in the
amount of 2D2 proliferation (Figure 3e). Despite the lack of
detectable pErk in 2D2:MOG cells, these results demonstrate that
this pathway is nonetheless utilized for activation.
Another mediator of T cell activation, c-Jun, is an important
target of Erk and the MAPK intermediate, JNK [44–46]. To
further explore the signaling profile during low potency peptide
interactions in self-reactive T cells, we assessed the kinetics of c-Jun
phosphorylation [42,47]. With either SMARTA:gp61 or 2D2
triggered by NFM, c-Jun is phosphorylated within 1 hour, while
phosphorylated c-Jun (p-c-Jun) is not detected in 2D2 CD4
+ T
cells stimulated with MOG until 3–6 hours later (Figure 3b and d).
Interestingly, the magnitude of the response also correlates with
the effective 2D affinity of the ligands, as more cells express both
pErk and p-c-Jun in SMARTA:gp61, followed by 2D2:NFM and
finally 2D2:MOG.
To further define the delayed signal transduction in T cells with
a low affinity for antigen, we assessed the kinetics of p38 MAPK
phosphorylation, which can influence differentiation of Th1 cells,
IFN-c production and possibly proliferation [48,49]. Analogous to
the phosphorylation kinetics of Erk, phosphorylation of p38
MAPK was similar in SMARTA:gp61 and 2D2:NFM but absent
in 2D2:MOG (Figure 4a and b). The percent of maximal
phosphorylation of either Erk or p38 is shown to compare the
kinetics of the response for each positive signaling mediator. For
both SMARTA:gp61 and 2D2:NFM, phosphorylation of p38
peaked by 5 minutes and declined to baseline by 30 to 60 minutes
(Figure 4b) while phosphorylation of Erk peaked by 30 to
60 minutes before declining (Figure 4a and Figure 3a and c).
However, with 2D2:MOG, there is no apparent accumulation of
Table 1. The 2D2 core MOG epitope is MOG39–48.
MOG Epitope 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 Proliferative Response
35–55 M E V G W Y R S P F S R V V H L Y R N G K +++
37–50 V G W Y R S P F S R V V H L +++
37–46 V G W Y R S P F S R 2
38–47 G W Y R S P F S R V +
39–48 W Y R S P F S R V V +++
40–49 Y R S P F S R V V H 2
41–50 R S P F S R V V H L 2
41–55 R S P F S R V V H L Y R N G K 2
42–50 S P F S R V V H L 2
44–54 F S R V V H L Y R N G 2
Splenocytes were harvested and dose response curves were generated with the indicated peptides up to a maximal concentration of 100 mM to determine the
proliferative capacity of 2D2 CD4
+ T cells. The nested sets of peptides were generated from the known full length MOG35–55 epitope. Three pluses represent
proliferation similar to the parent epitope, with each deduction of a plus representing a log shift in the dose required for maximal proliferation. A minus represents no
proliferation above background.
doi:10.1371/journal.pone.0032562.t001
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similar to the lack of detectable pErk accumulation (Figure 3
and 4a).
Previously, we have shown that the negative regulator SHP-1
plays a role in controlling an autoimmune response to MOG [50],
and in CD8+ T cells that the peak of SHP-1 activity occurs at
1 min in response to antigen [51]. Here, the kinetics of SHP-1
activity was analyzed following T cell activation. The phosphatase
assay employed allows for determination of the amount of free
phosphate released by immunoprecipitated SHP-1 from cell
lysates using a SHP-1 specific phosphorylated substrate. Both
SMARTA:gp61 and 2D2:NFM have up-regulated SHP-1 activity
at 1 minute (Figure 4c). Strikingly, the peak of SHP-1 activity was
delayed in 2D2 MOG stimulation (15 minutes) as compared to
SMARTA:gp61 and 2D2:NFM (Figure 4c). In addition to the
delay in peak activation, SHP-1 remains active in 2D2 MOG
stimulation throughout the 30-minute time course. This data
shows that multiple detectable signaling pathways are delayed or
undetectable in 2D2:MOG activation, including both positive and
negative feedback loops.
Expression of activation markers in low affinity CD4+ T
cells
This delay with signaling events could eventually translate to
delays in downstream responses. We analyzed the expression of
CD69, a T cell activation marker downstream of the Ras/Erk
MAP kinase pathway [52] by flow cytometry and found that 2D2
T cells stimulated with MOG showed a delay in CD69 up-
regulation (Figure 5a). Both SMARTA:gp61 and 2D2:NFM
stimulation resulted in complete up-regulation of CD69 by
4 hours whereas stimulation with MOG did not completely up-
regulate CD69 until 24 hours (Figure 5a). The magnitude of the
CD69 response was comparable at high doses of peptide at
24 hours with each peptide, but 2D2:MOG needed 10- to 100-
fold more antigen for maximal response (Figure 5c).
Similarly, the high affinity IL-2 receptor and marker of T cell
activation, CD25, was completely up regulated by 24 hours for all
peptides, yet MOG displayed a significant delay (Figure 5b and d).
In SMARTA cells, activation with gp61–80 resulted in peak CD25
expression by 6 hours (Figure 5b). This was similar to the kinetics
of CD25 expression in 2D2 cells stimulated with NFM; however,
2D2:MOG did not attain peak expression of CD25 until much
later (24 hours) (Figure 5b). Analogous to the delay in MAP kinase
signaling, up-regulation of activation markers was delayed in
2D2:MOG as compared to 2D2:NFM or SMARTA:gp61.
Delayed initiation of proliferation in low affinity CD4
+ T
cells
To extend our understanding of how low affinity interactions
may be time-dependent, the kinetics of cellular proliferation were
analyzed by CFSE dilution assay. In this assay there was a delay in
proliferation in 2D2 T cells with MOG as compared to either
SMARTA:gp61 or 2D2:NFM (Figure 6a). At 48 hours, the
majority of SMARTA:gp61 and 2D2:NFM CD4
+ T cells had
entered cycle and undergone between one and two divisions;
however, most of the CD4
+ T cells in MOG activation remained
undivided (Figure 6a). By 72 hours, all of the cells that entered
cycle underwent approximately the same number of divisions
regardless of the initiating peptide (Figure 6a). By day 3, there was
a noticeable increase over baseline in the cell numbers of both
SMARTA:gp61 and 2D2:NFM but not in 2D2:MOG, probably
due to the increased fraction of cells entering cycle (Figure 6b).
Interestingly, the total number of live CD4
+ T cells after 7 days in
culture was similar, in that SMARTA:gp61 (3.7610
664.9610
5
Figure 2. 2D2 splenocytes stimulated with MOG have a low functional avidity. (A) 6610
5 splenocytes from SMARTA or 2D2 mice were
stimulated with various doses of the indicated antigen for 72 hrs. and
3H-Thy was added during the last 18 hrs. to assess proliferation. (B) The
concentration of peptide needed to reach the half-maximal response (EC50 values, mM) were derived from the above proliferation assay using
GraphPad Prism. (C) The reciprocal EC50 was plotted against the effective 2D affinity. The open circle for 2D2:MOG denotes the uncertainty of
2D2:MOG affinity, as it was below 10
28 mm
4, the limit of detection for this assay. (D) 1.5610
6 splenocytes were stimulated for 24 hrs. and
supernatants were harvested to determine the amount of IL-2 by ELISA. (E) 1.5610
6 splenocytes were stimulated for 24 hrs. and supernatants were
harvested to determine the amount of IFN- c by ELISA. (F) 1.5610
6 splenocytes were stimulated with 10 mM of the indicated antigen and
supernatants were harvested (24 hrs. for IL-2 and IFN-c or 48 hrs. for IL-4) to determine the amount of cytokine by ELISA (P value: *=0.025, **=0.005,
***,0.002). All experiments were performed at least three times.
doi:10.1371/journal.pone.0032562.g002
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664.1610
5 cells) have a slightly
greater, though not statistically significant, number of cells than
2D2:MOG (2. 6610
662.3610
5 cells) (Figure 6b). These data
demonstrate that although the initiation of cellular proliferation is
delayed in 2D2 T cells stimulated with MOG, the cells that do
eventually enter the proliferative cycle retain the ability to divide
and can eventually reach similar cell numbers of higher affinity
TCRs.
Figure 3. 2D2 cells stimulated with MOG have no detectible pErk and delayed phosphorylation of c-Jun. Splenocytes from SMARTA or
2D2 mice were stimulated with 10 mM of the indicated antigen and signaling events were assessed. (A) A representative plot of pErk expression
assessed at various time points by flow cytometry, gated on CD4
+ cells. (B) A representative plot of p-c-Jun expression assessed at various time points
by flow cytometry, gated on CD4
+ cells. Graphical representation of averaged p-Erk (C) and p-c-Jun (D) expression are from at least three independent
experiments at various time points. (E) Cell proliferation was assessed after treatment with the Erk-specific MEK inhibitor U0126. All experiments were
repeated at least three times.
doi:10.1371/journal.pone.0032562.g003
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presentation of antigen by APCs, requiring as little as a few hours
to trigger a response [53–55]. Stimulation of 2D2 cells with NFM,
but not MOG, allows for complete up-regulation of CD69 and
CD25 by approximately 6 hours, whereas both peptides up-
regulate activation markers by 24 hours (Figure 5a and b). To
explore the importance of the time of antigen presentation as it
relates to the apparent delay in MOG:2D2, the extent of
activation was examined at 24 hours after various periods of T
cell to APC contact time. CD4
+ T cells were allowed 3, 6, 12 or
24 hours of contact time before analysis of CD69 and CD25
expression at 24 hrs. In 2D2:NFM, nearly half of the cells up-
regulated CD69 and CD25 within 3 hours of APC contact time;
however it took at least 12 hours for 2D2:MOG to up-regulate the
Figure 4. 2D2 T cells stimulated with MOG have an altered signaling program. (A) Splenocytes from SMARTA or 2D2 mice were stimulated
with 10 mM of the indicated antigen and the percent of maximal Erk phosphorylation was assessed at various time points by flow cytometry (gated
on CD4
+ cells). (B) Splenocytes from SMARTA or 2D2 mice were stimulated with 10 mM of the indicated antigen and the percent of maximal p38
MAPK phosphorylation was assessed at various time points by flow cytometry (gated on CD4
+ cells). (C) Splenocytes from SMARTA or 2D2 mice were
stimulated with 10 mM of the indicated antigen and SHP-1 phosphatase activity was assessed at various time points using a colorimetric assay for free
phosphate with a phosphorylated peptide substrate specific for SHP-1. The percent of maximal response was assessed to highlight the kinetics of the
signaling response and was calculated using GraphPad Prism/ All experiments were repeated at least three times.
doi:10.1371/journal.pone.0032562.g004
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12 hours of contact time, nearly all of NFM:2D2 CD4
+ T cells up
regulated CD69 and CD25. At 24 hours of APC contact time,
both NFM and MOG allowed near complete activation of the cells
(Figure 6c). This data shows that 2D2 T cells stimulated with a low
affinity peptide need an extended period of time in contact with
pMHC to reach maximal activation in comparison to higher
affinity interactions.
Discussion
It is generally assumed that auto-reactive T cells are of lower
affinity than T cells specific for foreign antigen. Our lab has shown
that in responses to a foreign antigen, gp61, or a self-peptide,
MOG, the polyclonal T cell repertoire encompasses a similar wide
breadth of affinities with the response to MOG including more low
affinity T cell clones [10]. To further understand the relationship
of affinity to T cell response, we examined viral specific and self-
reactive TCR transgenic T cells (SMARTA and 2D2, respective-
ly). We found that 2D2 T cells were of low affinity, compared to
SMARTA T cells, and failed to be detected in the 2D micropipette
assay or to react with a peptide-specific tetramer by flow
cytometry. Surprisingly given their low affinity, we and many
others have employed MOG-activated 2D2 T cells to induce EAE,
indicating low TCR affinity for antigen does not preclude
autoimmune disease [19,22,50,56–58].
An alternative explanation for the lack of tetramer staining and
2D binding in 2D2 cells could relate to the findings that peptides
presented by MHC class II, especially murine I-A
b, can bind the
MHC in different registers through the use of different MHC
anchor residues [28–31]. Epitope mapping in 2D2 T cells revealed
that the core encompasses MOG39–48, the epitope engineered in
the MOG:I-A
b tetramer (Table I). Additionally, we have found
that the MOG:I-A
b monomer identifies the majority (.70%) of
the CD4
+ T cells in the CNS at the peak of EAE [10]. The lack of
tetramer staining and undetectable 2D affinity is unlikely due to an
alternative register recognized by 2D2 T cells, but instead caused
by the considerably lower affinity of this TCR to MOG.
The low affinity of 2D2 T cells for MOG led to a qualitative
difference in the kinetics of T cell activation (Figure 3, 4, 5, 6),
apparent as a delay in signaling, up-regulation of activation
markers, and subsequent proliferation. However, analysis at later
time points show that the T cells can compensate for this apparent
early defect (Figure 6). This indicates that, under appropriate
conditions that include continued access to antigen (Figure 6), time
can offset low affinity for a ligand and allow for a slow
accumulation of signaling intermediates that eventually lead to a
complete response. This idea of qualitative as opposed to
quantitative differences in peptide antigens as it relates to T cell
responses has also been reported elsewhere and suggests that
following CD4 TCR ligation, signaling pathways can diverge to
allow for various functional outcomes of demonstrable TCR:anti-
gen interactions [42,59].
There has been much interest in determining the early signaling
events in T cells after TCR ligation; however, the kinetics of the
various signaling intermediaries involved and how timing affects
the net outcome of signaling is still under investigation. The timing
of signal propagation through both positive and negative
mediators may play a key role in modulating T cell activation
with low potency ligands. In this study we aimed to assess a few of
the many potential differences in activation kinetics of a high
affinity viral-specific T cell from SMARTA mice to a low affinity
self-reactive T cell from 2D2 mice. Mathematical modeling of
TCR signal transduction theorizes that positive and negative
feedback loops activated during T cell interactions with antigen
presenting cells allow for discrimination between a range of ligand
affinities [39,60]. In fact, one model proposes a balance between
the positive signals driven by Erk activation and negative signals
driven by SHP-1 to regulate T cell activation [39]. Here, we show
that even with undetectable Erk or p38 phosphorylation and
Figure 5. 2D2 CD4
+ T cell stimulation with MOG results in delayed expression of activation markers. SMARTA or 2D2 splenocytes were
stimulated with 10 mM antigen for various time points and CD69 (A) and CD25 (B) expression on CD4
+ cells was analyzed by flow cytometry. SMARTA
or 2D2 splenocytes were stimulated with various concentrations of antigen for 24 hrs. and CD69 (C) and CD25 (D) expression on CD4
+ cells was
analyzed by flow cytometry. Experiments were performed at least three times.
doi:10.1371/journal.pone.0032562.g005
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encounter low affinity ligands can still undergo full activation. This
suggests that these feedback mechanisms may be more compli-
cated than initially described and that a smoldering positive signal
may be able to drive T cell activation under the appropriate
conditions.
Importantly, in addition to differences in positive signaling, we
show that there is delayed, but sustained up-regulation of SHP-1
activity in 2D2:MOG interactions, but not in NFM (or
SMARTA:gp61) stimulation (Figure 4). We, and others, have
shown an important role for SHP-1 in regulating responses to low
potency antigens [50,51,61,62]. Specifically, we have shown that
an LCMV mutant epitope allowing for viral escape induces
delayed SHP-1 activation in CD8+ T cells [51]. In these experi-
ments, the quick burst of SHP-1 activity in agonist stimulation is
not unexpected, as this denotes the initial burst of signaling
initiated by a potent pMHC complex. The quick recovery of SHP-
1 to an inactive state during strong peptide interactions
(SMARTA:gp61 and 2D2:NFM) supports the licensing of that
cell to undergo activation and proliferation. The delayed but
sustained activation of SHP-1 following MOG stimulation
indicates an altered signaling profile in these cells and corresponds
with the lower functional avidity of 2D2 T cells for MOG. We
suggest that the interplay between delayed or negligible levels of
positive signaling (c-Jun or Erk and p38, respectively) and the
sustained negative activity of SHP-1 synergistically affects the
outcome of T cell signaling in low affinity TCR interactions;
however, given adequate time cells are able to overcome this delay
in activation to divide and survive.
The absence of measured MOG reactivity using specific
tetramer or the micropipette analysis may very well indicate the
importance of time for these affinity measures. Delayed on-rates or
very rapid off-rates could affect the ultimate outcome of T cell
stimulation. However, with the current assays it is difficult to
distinguish these possibilities. Peptide:MHC tetramers work by
increasing the avidity of the TCR:pMHC by allowing an
improved chance of interaction between TCR and the multimeric
structure [63,64], which would be dependent on the binding
kinetics [10]. Time is similarly important for the micropipette
measurements as low affinity translates to a low binding
probability [5,10]. Longer antigen exposure time equates to a
larger total number of TCR:pMHC encounters, hence a larger
cumulative number of TCR bonds, which increases the binding
probability [65]. Previously, we have shown that 2D2 T cells
require high expression levels of TCR for response, supporting a
requirement of an increased number of TCR bonds [21]. Thus,
the persistent exposure of an autoimmune antigen may be able to
compensate for its low affinity to yield a cumulative number of
TCR bonds sufficient for T cell activation.
We have reported that the average TCR affinity for a polyclonal
MOG-specific population is on the order of 10
25 mm
4 [10]. This
implies that 2D2 cells represent the lowest affinity T cells in the
spectrum of polyclonal TCR affinities during an autoimmune
response. When compared to the CD8+ OT-I system, the 2D2
affinity for MOG is even below the level reported for the
ovalbumin TCR antagonists [5]. This indicates that 2D2 T cells
are of very low affinity and raises the issue of how T cells with such
low affinity are relevant to T cell responses. Normally, during an
acute infection the foreign antigen is transiently expressed for a
limited amount of time [11,66]. Self-antigens on the other hand
are constantly available to be presented to T cells, potentially
extending the length of time for triggering of the T cell [15,16].
Taken together, this data implies that analysis of T cell activation
over a short time frame may not allow for a full understanding of
agonistic properties of antigens, specifically in autoreactive T cells
that are able to encounter low affinity peptides over extended
periods of time.
Interestingly, the importance of time and the availability of
antigen in the ability of T cells to reach the thresholds for signaling
events highlights the fact that autoreactive T cells may be able to
use time, through either sustained or short repeated engagements,
to achieve a response [67–69]. Upon multiple instances of
Figure 6. MOG stimulation results in delayed initiation of
proliferation but eventual accumulation of CD4
+ Tc e l l s .
Splenocytes from SMARTA or 2D2 mice were CFSE labeled and
stimulated with 10 mM of the indicated antigen for various times. (A)
Representative plots from at least three independent experiments show
CFSE dilution of CD4
+ cells, assessed by flow cytometry, to detect
proliferation at indicated times. (B) On various days, total CD4
+ T cell
numbers were assessed using BD Trucount tubes (BD Biosciences) to
gauge cellular accumulation after peptide stimulation (On Day 7,
SMARTA:gp61 and 2D2:NFM, p=0.1; SMARTA:gp61 and 2D2:MOG
p=0.5; 2D2:NFM and 2D2:MOG p=0.2). (C) After the indicated APC
contact time, CD4+ T cells were MACS purified to remove the cells from
the APCs. The percent of CD25+ and CD69+ CD4+ T cells was assessed
by flow cytometry at 24 hours, as indicated on the x-axis. Experiments
were performed at least three times; p values were generated using
student’s t-test on GraphPad Prism.
doi:10.1371/journal.pone.0032562.g006
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method to limit damage to the host in response to ineffective
clearance of an infection [70,71]. Potentially, the smoldering T cell
response observed during autoimmune disease may result, at least
in part, from the activation of very low affinity T cells that can




This study was performed in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health.
MOG35-55 specific TCR transgenic 2D2 mice (Jackson Labs,
C57BL/6-Tg(Tcra2D2,Tcrb2D2)1Kuch/J) and gp61–80 specific
TCR transgenic SMARTA mice [17,18] were bred, housed and
used with specific approval from the Institutional Animal Care and
Use Committee-approved protocol of the Emory University
Department of Animal Resources facility (IUCAC Number:
DAR-2000870-061414). All mice were used for experiments at
6–8 weeks of age.
Peptides and Reagents
LCMV gp61–80 (GLNGPDIYKGVYQFKSVEFD) and mouse
NFM15–35 (RRVTETRSSFSRVSGSPSSGF) and MOG35–55
(MEVGWYRSPFSRVVHLYRNGK) were synthesized in-house
using F-moc chemistry on the Prelude peptide synthesizer (Protein
Technologies). Culture medium consisted of RPMI 1640 medium
(Mediatech) supplemented with 10% FBS (HyClone), 2 mM L-
glutamine (Mediatech), 0.01 M HEPES buffer (Mediatech),
100 mg/ml gentamicin (Mediatech), and 2610
25 M 2-ME
(Sigma-Aldrich). Oxidation buffer consisted of 20 mM Tris-HCl
(pH 7.5), 150 mM NaCl, 1 mM Na2EDTA, 0.5% Igepal, 1 mM
Na3VO4, and 1/100 protease inhibitor cocktail I (Calbiochem) to
inhibit degradation of cellular proteins following lysis of the cells.
2D TCR affinity analysis by micropipette adhesion
frequency assay
Human red blood cells (RBCs) were isolated from healthy
volunteers at the Georgia Institute of Technology in accordance
with specific approval from the Georgia Institute of Technology
Institutional Review Board (protocol number: H07343) and
prepared as previously described [5]. In accordance with ethical
guidelines, written and informed consent was obtained from all
anonymous volunteers prior to blood collection. RBCs were
coated with various concentrations of biotin-X-NHS (Calbio-
chem), followed by 0.5 mg/ml streptavidin (Pierce) and then 1–




b monomers were provided by the NIAID
Tetramer Core Facility at Emory University. The pMHC-coated
RBCs were stained with anti-MHC II FITC Ab (M5/114.15.2;
BioLegend) and T cells were stained with anti-TCRb FITC Ab
(H57–597; eBioscience). The site densities of I-A
b monomers per
RBC and TCRs per T cell were derived using anti-FITC MHC II,
anti-TCR antibodies, and FITC MESF beads (Bangs Labs) and
normalized for the F/P ratios of the antibodies.
The details of the micropipette adhesion frequency assay have
been described [5,20]. Briefly, the adhesion was measured
following contact of a single T cell and pMHC-coated RBC on
opposing micropipettes. At the end of the contact time, the T cell
was retracted and the presence of adhesion (indicating
TCR:pMHC ligation) was observed microscopically by elongation
of the RBC membrane. The adhesion frequency (Pa) was
calculated by performing the contact-retraction 50 times per T
cell-RBC pair. A 5 second contact time was chosen in all
experiments because the Pa had reached equilibrium and
remained constant despite further increase in contact time. The
effective 2D affinity (AcKa) was calculated using the average Pa
according to the following equation:
AcKa~{ln 1{Pa 5s ðÞ ½  = mrml ðÞ
where mr and ml reflect the receptor (TCR) and ligand (pMHC)
densities, respectively.
T cell Tetramer Staining
As performed previously, splenocytes from SMARTA or 2D2
mice were incubated for 7 days at 37uC with either gp61–80 or
MOG35–55, respectively [10]. Live, previously activated cells
were isolated using a Ficoll gradient, washed, and stained for
tetramer analysis. Live cells were incubated with 4 mg/ml
MOG38–49:I-A
b (8–20 h) [27], GP66–77:I-A
b tetramers (3–4 h), or
hCLIP103–117:I-A
b (NIAID Tetramer Core Facility at Emory
University, Atlanta, GA) in complete RPMI at 37uC. The cells
were washed with buffer containing 16 PBS, 0.1% BSA, and
0.05% sodium azide. Cells were then stained with anti-CD4-APC
(RM4.5) (BD-Bioscience) and 7-AAD for 30 minutes on ice. The
percentage of tetramer-PE positive cells was determined in live (7-
AAD negative) CD4-positive populations. All flow cytometric
analysis was performed on a FACSCalibur (BD) and data were




5 naive splenocytes from 2D2
or SMARTA mice were incubated in a 96-well plate with the
indicated concentration of peptide. In some assays (as indicated),
cells were pretreated for 30 min with the MEK inhibitor U0126
(Promega) at 10 mM. After 48 h in culture, cells were labeled with
0.4 mCi/well [
3H]-thymidine. After 18–24 h, the plates were
harvested on a FilterMate harvester (Packard Instrument) and
analyzed on a 1450 LSC Microbeta TriLux counter (PerkinElmer)
[72].
For CFSE analysis, naı ¨ve splenocytes from either 2D2 or
SMARTA mice were labeled with CFSE and 1.5610
6 cells were
incubated in 24-well plates with 10 mM peptide for a given time
period before being stained with CD4 APC and 7-AAD and
analyzed on a FACSCalibur.
T cell IL-2 ELISA
Splenocytes (1.5610
6) from 2D2 or SMARTA mice were
incubated in a 24-well plate with the indicated concentration of
peptide. After 24 h in culture, supernatants were removed and
placed on microtiter plates coated with purified anti-IL-2 (5 mg/ml
clone JES6-1A12; BD Pharmingen) overnight at 4uC. Recombi-
nant IL-2 (BD Pharmingen) was used as a standard. Captured
cytokines were detected using biotinylated anti-IL-2 (100 mg/ml
JES6-5H4, 100 ml per well; BD Pharmingen) and detected using
alkaline phosphatase-conjugated avidin (Sigma-Aldrich) and p-
nitrophenyl phosphate substrate (Bio-Rad). Colorimetric change
was measured at dual wavelengths of 405 and 630 nm on a
Microplate Autoreader (Biotek Synergy HT) [72].
Analysis of T cell signaling
For time courses that included short peptide stimulation
(#60 min), fibroblasts transfected with I-A
b (clone FT7.1C6)
[73] were plated out in 24-well plates and incubated until
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1–2 h and washed. Naive splenocytes were run over a Ficoll
gradient and 3610
6 cells were added to each well of pre-pulsed
fibroblasts. Cells were spun at 600 rpm for 1 min to begin peptide
stimulation and allowed to incubate at 37uC for the indicated time
points. For time courses with only long peptide stimulation
($60 min), naı ¨ve splenocytes (3610
6) were stimulated with the
indicated dose of antigen for the duration of the time course.
For analysis of protein phosphorylation, cells were taken off
fibroblasts at the indicated time points and approximately
300,000–500,000 splenocytes were stained for intracellular
signaling events. Cells were fixed for 10 min with methanol free
formaldehyde at room temperature and permeabilized with 100%
ice-cold methanol for 10 min on ice. Cells were then stained with
antibodies to CD4 (RM4-5, BD Biosciences), p-p44/42
(D13.14.4E, Cell Signaling), p-c-Jun (KM-1, Santa Cruz Biotech-
nology), and/or phospho-p38 MAPK (3D7, Cell Signaling) for
30 min on ice, washed, and immediately analyzed by flow
cytometry. Flow cytometry was performed on a BD FACSCalibur
and data were processed using FlowJo software (Tree Star). FACS
wash consisted of PBS, 0.05% sodium azide, and 0.1% BSA.
For analysis of SHP-1 activity, cells were taken off pre-pulsed
fibroblasts at the indicated time points, lysed in oxidation buffer
and spun at 14,000 rpm for 5 min. SHP-1 was immunoprecipi-
tated with 2 mg of anti-SHP-1 Ab (C19, Santa Cruz biotechnol-
ogy) overnight, collected with protein A beads for 1 h, and protein
A beads were washed once with oxidation buffer and twice with
wash buffer (25 mM HEPES (pH 7.2), 50 mM NaCl, and
2.5 mM EDTA). SHP-1 substrate peptide (AEEEIpYGEFEA)
was added at a final concentration of 1 mM in Tyr assay buffer
with 5 mM DTT (Upstate Biotechnology) and incubated with
immunoprecipitated SHP-1 for 1 h at 37uC. Released phosphate
was detected by addition of malachite green (Upstate Biotechnol-
ogy) [51,74,75].
Analysis of Surface Markers
For continuous peptide stimulation, splenocytes (3610
6) from
2D2 or SMARTA mice were stimulated for the indicated time
points in 24-well plates, washed in FACS buffer and surface
stained for CD4 (RM4-5, BD Bioscience), CD25 (PC61, BD
Bioscience), and CD69 (H1.2F3, BD Bioscience) for 30 min on ice.
Cells were then washed, stored at 4uC and run on a flow cytometer
within 24 hours.
For stimulation with various APC contact times, splenocytes
(3610
6) from 2D2 mice were stimulated for the indicated time
points in a 24-well plate prior to CD4
+ MACS purification carried
out as per manufacturer’s instructions (CD4
+ T Cell Isolation Kit,
MACS Miltenyi Biotec). The isolated CD4
+ T cells were then
resuspended in R10, placed in a well in the 24-well plate and
incubated for the remaining time in the 24 hour time course, to
allow for further protein production and up-regulation after the
limited stimulation time. At 24 hours, the remaining cells were
also purified and all cells were stained on ice for 30 minutes with
CD69 FITC, CD4 PE, 7AAD, CD25 APC and analyzed on a
FACSCalibur flow cytometer.
Statistical Analysis
All data analysis was performed on GraphPad Prism (Software
for Science).
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